In short
Clinical trials of ARLOCABTAGENE AUTOLEUCEL are studying its long-term safety and how well it works in people with relapsed or refractory multiple myeloma. The research also includes long-term follow-up of patients who previously received gene-modified T cells. These trials look at safety, survival, disease control, and growth in children.
Key points
- ARLOCABTAGENE AUTOLEUCEL is being studied in clinical trials for people with relapsed or refractory multiple myeloma and in long-term follow-up after earlier gene-modified T cell treatment. One study is Phase 3 and compares a GPRC5D-directed CAR T cell therapy with standard treatments. Another study is Phase 4 and follows adults and children for up to 15 years after treatment. The trials measure safety, long-term persistence of the therapy, survival, disease progression, and minimal residual disease. In children, the follow-up study also tracks growth and sexual maturity. The available trial data show that the research is focused on both treatment benefit and long-term safety.
Trial overview
Clinical trials of ARLOCABTAGENE AUTOLEUCEL are looking at both long-term follow-up after earlier gene-modified T cell treatment and a Phase 3 study in relapsed or refractory multiple myeloma. The available trial data show two different goals: to monitor safety over many years and to test whether the study treatment works better than standard options in myeloma.
Who can join the studies
One study includes all adult and paediatric subjects who received at least one genetically modified T cell infusion in a previous Celgene-sponsored study. The Phase 3 study includes participants with relapsed or refractory multiple myeloma who have been exposed to lenalidomide.
This means the studies are not open to everyone; each trial has a specific group based on past treatment and current disease status.
What is being measured
The Phase 4 follow-up study measures delayed adverse events, which are side effects that happen later after treatment, and it also checks whether the gene-modified T cell product stays in the body over time. It also looks for replication competent lentivirus, a safety check for certain gene therapy products, and it tracks growth and sexual maturity in children.
For participants with a cancer diagnosis, the study also measures overall survival and whether the disease progresses during follow-up. In the Phase 3 myeloma study, the main outcomes are progression free survival and minimal residual disease-negative complete response, which means no signs of myeloma can be found in the body.
Trial phases and status
The long-term follow-up study is a Phase 4 trial and is listed as authorised. Phase 4 studies usually take place after a treatment has already been given in earlier research and are used to watch long-term safety and results.
The multiple myeloma trial is a Phase 3 study and is also listed as authorised. Phase 3 studies compare a new treatment with standard care to see which works better and how well it controls the disease.
Study designs and treatment groups
The long-term follow-up study is interventional and has a large enrollment of 1410 people. Its brief summary says the study will assess delayed side effects, long-term persistence of gene-modified T cells, safety checks for lentiviral vector products, long-term efficacy, and growth and maturity in younger participants.
The Phase 3 multiple myeloma study has an enrollment of 440 people and compares a GPRC5D-directed CAR T cell therapy with standard treatments such as daratumumab with pomalidomide and dexamethasone, or carfilzomib with dexamethasone. The study also uses other medicines in the treatment plan, including cyclophosphamide, fludarabine phosphate, dexamethasone, pomalidomide, carfilzomib, daratumumab, and tocilizumab, as listed in the trial record.
What the trial results mean for patients
For patients, these studies are mainly asking two questions: does the treatment help control disease, and is it safe over the long term? The answer is being measured not only by cancer response, but also by long follow-up for late effects, especially in children and in people who had earlier gene-modified T cell treatment.
The trial data show a strong focus on careful monitoring after treatment, which is important because some effects may appear months or years later. In the myeloma study, the main goal is to see whether the new CAR T cell approach can improve the chance of living longer without the disease getting worse.